alloreactivity

alloreactivity

the reaction of lymphocytes or antibodies with alloantigens.
References in periodicals archive ?
The TALEN -based gene editing (knock-out of the TCR-alpha and CD52 genes) is designed to suppress T-cell alloreactivity and confer resistance to alemtuzumab to the T-cells.
Natural killer cell alloreactivity in allogeneic hematopoietic transplantation.
lymphocyte proliferation [proliferating cell nuclear antigen (PCNA) measurement], expression of specific T- and B-cell surface antigens, and intracellular markers (such as cytokine expression, cytokine mRNA expression, and drug concentration); (c) measure soluble cytokines; (d) measure interferon-[gamma] (IFN-[gamma]) alloreactivity [enzyme-linked immunosorbent spot (ELISPOT)]; and (e) balance T-effector cells/ T-regulatory cells (Tregs) (alloreactivity vs tolerance).
Impact of humoral alloreactivity early after transplantation on the long-term survival of renal allografts.
6,16,17] Their combined effects result in an increased immune response and increased organ alloreactivity.
This work gathers the latest research in the field of transplantation immunology, in areas such as T-cell immunity, antigen presentation, alloreactivity, pancreas and islet cell transplantation, allogenic bone marrow transplantation, models of tolerance induction, xenotransplantation, and the swine leukocyte complex.
Offering explanation for the possible value of MSCs in treating GVHD, researchers noted that MSCs derived from adult bone marrow have the capacity to differentiate into several types of mesenchymal tissue and are proven to inhibit T-cell alloreactivity in vitro.
Data presented in the poster show the careful characterization of the functional specificity of the isolated CTL for HBV, also ensuring the absence of autoreactivity (reaction to the patient's own cells or tissues) or alloreactivity (reaction to the filler cells used in the REM process).
Because of the morphologic similarities between such lesions and OB, these lesions may result from the same pathologic process and could be the result of tissue repair and remodeling in response to graft injury that was caused by repeated cycles of rejection or ongoing subclinical alloreactivity.
In one study, the islet graft-specific cellular auto- and alloreactivity in peripheral blood from patients with failing islet allografts were compared to the reactivities in patients with functional grafts.
In previous studies, this strategy showed an ability to control T cell alloreactivity after bone marrow or solid organ transplantation, but studies had not been conducted evaluating the technology's ability to control harmful, virus-induced immune responses.